{"name":"Aqualung Therapeutics Corp.","slug":"aqualung-therapeutics-corp","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ALT-100","genericName":"ALT-100","slug":"alt-100","indication":"Other","status":"phase_2"},{"name":"ALT-100 mAb","genericName":"ALT-100 mAb","slug":"alt-100-mab","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ALT-100","genericName":"ALT-100","slug":"alt-100","phase":"phase_2","mechanism":"ALT-100 is an investigational immunotherapy designed to modulate immune responses, likely through targeting specific immune checkpoints or enhancing T-cell activation.","indications":[],"catalyst":""},{"name":"ALT-100 mAb","genericName":"ALT-100 mAb","slug":"alt-100-mab","phase":"phase_2","mechanism":"ALT-100 mAb is a monoclonal antibody that targets an unspecified molecular target.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxONGFpRVkwTTNZMUlaRzFxZWFVSWdhbHdOZGRTTDdVbWhueFNuRWF0X3NEa3ZLc0hzRzBwbHQ4eE1wVWFrMFlxV2NBZUlMeDJkRGJlVXkwWGp2Q2YzUFRpVUk2cXlaMjBhbkpVN2JOcjhWc3lSLWhnRHpBNE5STERPSUpJWVdMdGJ5QUpSTzgtX3NYZjMxeHpLRklvRQ?oc=5","date":"2026-03-19","type":"pipeline","source":"openPR.com","summary":"Acute Respiratory Distress Syndrome Pipeline 2026: Therapies - openPR.com","headline":"Acute Respiratory Distress Syndrome Pipeline 2026: Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"globenewswire.com","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - globenewswire.com","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-07-19","type":"pipeline","source":"PR Newswire","summary":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer B","headline":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Ba","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNTnliMTZNM3l5Njh2TFEzc0tLOUdSck1IaWVkVjBzMUlfRzlXelVTQTJYOV92OGZGd1NQSlBtT2FDX0J4TjhuUHNGZzNDYkw3T3J3Qk5xWUdvMnBWT041cEpKUWQzb2tYN0FXd0ZzY2hSb2xsLVY3aldueDVyNmFSeGtBdV9JTFo2Y0s3UmZ1a1pLM2VNUTVtaEhtZ3I2RWJ3eUE?oc=5","date":"2022-08-30","type":"trial","source":"globaldata.com","summary":"Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - globaldata.com","headline":"Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Upda","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}